SciELO - Scientific Electronic Library Online

 
vol.33 issue3Rheumatoid factor in ANCA associated vasculitisExperience on the health-disease-care process in patients with rheumatoid arthritis belonging to the Wichí community of Mission Chaqueña “El Algarrobal”, Salta author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista argentina de reumatología

Print version ISSN 0327-4411On-line version ISSN 2362-3675

Abstract

MAMANI ORTEGA, María Lourdes et al. Vaccination against SARS-CoV-2 in patients with systemic sclerosis in Argentina: preferences, access and adherence to the vaccination plan. Rev. argent. reumatolg. [online]. 2022, vol.33, n.3, pp.123-128. ISSN 0327-4411.  http://dx.doi.org/10.47196/rar.v33i3.663.

Introduction:

in patients with autoimmune rheumatic diseases, the systematic and sequential application of a series of vaccines is recommended for the prevention of communicable diseases. The objective was to estimate the proportion of patients with systemic sclerosis (SSc) who received vaccination against coronavirus (SARS-CoV-2).

Materials and methods:

since may to september 2021, an anonymous survey was sent by email or messaging app, containing questions to assess adherence to the recommended vaccination schedule in patients with rheumatic diseases, as well as fears, preferences and adherence to vaccination schedule against SARS-CoV-2.

Results:

295 patients with SSc were included. 68.81% were vaccinated for SARS-CoV-2 with at least one dose, 48.7% of this group had two doses. 84.75% reported talking to their doctor about their general vaccination schedule. Only 5.4% had all four vaccines. 93.56% expressed willingness to be vaccinated against SARS-CoV-2, 56.27% preferred the Sputnik V vaccine. 7.46% expressed their willingness to not be vaccinated. The factors that most frequently influenced adherence to vaccination were fear of contracting SARS-CoV-2 infection (86.1%) and adverse reactions (23.05%).

Conclusions:

we highlight the fact that only 6 months after vaccination against SARS-CoV-2 became available, half of the patients with SSc had the full recommended schedule.

Keywords : autoimmune systemic diseases; systemic sclerosis; COVID-19 vaccine.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )